MoonLake Immunotherapeutics (MLTX)
NASDAQ: MLTX · Real-Time Price · USD
17.96
-1.45 (-7.47%)
At close: Apr 10, 2026, 4:00 PM EDT
18.37
+0.41 (2.29%)
After-hours: Apr 10, 2026, 7:51 PM EDT
MLTX Stock Forecast
Stock Price Forecast
The 12 analysts that cover MLTX stock have a consensus rating of "Buy" and an average price target of $27.5, which forecasts a 53.12% increase in the stock price over the next year. The lowest target is $5.00 and the highest is $70.
Price Target: $27.5 (+53.12%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for MLTX stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 6 | 6 |
| Buy | 2 | 2 | 2 | 3 | 3 | 3 |
| Hold | 2 | 2 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 2 | 2 | 2 | 2 |
| Total | 9 | 9 | 9 | 10 | 12 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| BTIG | BTIG | Strong Buy Reiterates $30 | Strong Buy | Reiterates | $30 | +67.04% | Mar 30, 2026 |
| Wolfe Research | Wolfe Research | Sell → Buy Upgrades $12 → $24 | Sell → Buy | Upgrades | $12 → $24 | +33.63% | Mar 23, 2026 |
| Rothschild & Co | Rothschild & Co | Hold → Strong Buy Upgrades $12 → $40 | Hold → Strong Buy | Upgrades | $12 → $40 | +122.72% | Mar 19, 2026 |
| Clear Street | Clear Street | Strong Buy Maintains $45 → $70 | Strong Buy | Maintains | $45 → $70 | +289.76% | Mar 11, 2026 |
| RBC Capital | RBC Capital | Hold Maintains $12 → $13 | Hold | Maintains | $12 → $13 | -27.62% | Mar 2, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
20.74M
EPS This Year
-3.69
from -3.53
EPS Next Year
-3.74
from -3.69
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | n/a | 43.6M | |||
| Avg | n/a | 20.7M | |||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -2.66 | -2.73 | |||
| Avg | -3.69 | -3.74 | |||
| Low | -4.16 | -5.10 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.